Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Fate Therapeutics, Inc. (NASDAQ: FATE)
FATE Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-25.50%
Analyst Rating:
BUY
Analyst Forecast (1yr):
181.50%
FATE Stock Analysis
FATE
PE Ratio:
FATE
PEG Ratio:
Not Available
FATE
Forward EPS Growth (12 month):
0.00%
FATE
PS Ratio:
41
FATE
PSG Ratio:
-3.1
FATE
Forward Revenue Growth (12 month):
-13.00%
FATE Articles
No data was found